Sirturo Approval History

  • FDA approved: Yes (First approved December 28th, 2012)
  • Brand name: Sirturo
  • Generic name: bedaquiline
  • Company: Janssen Research & Development, LLC
  • Treatment for: Tuberculosis, Resistant

Sirturo (bedaquiline) is an oral diarylquinoline antimycobacterial drug indicated for the treatment of pulmonary multi-drug resistant tuberculosis.

FDA Approval History for Sirturo

DateArticle
Dec 31, 2012Approval FDA Approves Sirturo to Treat Multi-Drug Resistant Tuberculosis
Sep  5, 2012U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
Jul  2, 2012Janssen Research & Development Submits New Drug Application to FDA for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline (TMC207)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web5)